BRPI0511616A - compostos - Google Patents
compostosInfo
- Publication number
- BRPI0511616A BRPI0511616A BRPI0511616-3A BRPI0511616A BRPI0511616A BR PI0511616 A BRPI0511616 A BR PI0511616A BR PI0511616 A BRPI0511616 A BR PI0511616A BR PI0511616 A BRPI0511616 A BR PI0511616A
- Authority
- BR
- Brazil
- Prior art keywords
- disorders
- compounds
- inhibitors
- preparation
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Communicable Diseases (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- AIDS & HIV (AREA)
- Biotechnology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
Abstract
COMPOSTOS. A presente invenção refere-se a pirimidinas substituídas selecionadas, sua preparação, composições farmacêuticas contendo as mesmas e seu uso como inibidores de uma ou mais cinases protéicas, e por conseguinte seu uso no tratamento de distúrbios proliferativos, distúrbios virais e/ou outros distúrbios.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0411791.7A GB0411791D0 (en) | 2004-05-26 | 2004-05-26 | Compounds |
PCT/GB2005/002134 WO2005116025A2 (en) | 2004-05-26 | 2005-05-26 | 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0511616A true BRPI0511616A (pt) | 2008-01-02 |
Family
ID=32671118
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0511616-3A BRPI0511616A (pt) | 2004-05-26 | 2005-05-26 | compostos |
Country Status (11)
Country | Link |
---|---|
US (1) | US20090137572A1 (pt) |
EP (1) | EP1756098A2 (pt) |
JP (1) | JP5026259B2 (pt) |
CN (1) | CN1989138A (pt) |
AU (1) | AU2005247682A1 (pt) |
BR (1) | BRPI0511616A (pt) |
CA (1) | CA2566051A1 (pt) |
GB (1) | GB0411791D0 (pt) |
IL (1) | IL179508A0 (pt) |
MX (1) | MXPA06013632A (pt) |
WO (1) | WO2005116025A2 (pt) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20070083836A (ko) * | 2004-10-28 | 2007-08-24 | 아이알엠 엘엘씨 | 헷지혹 경로 조절제로서의 화합물 및 조성물 |
CN101203500B (zh) * | 2005-01-25 | 2013-08-21 | 格利尼公司 | 取代的芳胺化合物和它们作为5-ht6调节剂的用途 |
AU2006209216A1 (en) | 2005-01-25 | 2006-08-03 | Galenea Corp | Substituted arylamine compounds and their use as 5-HT6 modulators |
US7514566B2 (en) | 2006-01-18 | 2009-04-07 | Amgen, Inc. | Thiazole compounds and methods of use |
GB0609530D0 (en) * | 2006-05-12 | 2006-06-21 | Cyclacel Ltd | Combination |
WO2007132220A1 (en) * | 2006-05-12 | 2007-11-22 | Cyclacel Limited | Combination of a 2-substituted-4-heter0aryl-pyrimidine amine with a cytotoxic drug and use thereof in the treatment of a proliferative disorder |
WO2007132221A1 (en) * | 2006-05-12 | 2007-11-22 | Cyclacel Limited | Combined anticancer pyrimidine-thiazole aurora kinase inhibitors |
JP2010533715A (ja) | 2007-07-17 | 2010-10-28 | アムジエン・インコーポレーテツド | 複素環系pkb調節剤 |
AU2008276512A1 (en) | 2007-07-17 | 2009-01-22 | Amgen Inc. | Thiadiazole modulators of PKB |
US20110190280A1 (en) * | 2007-08-29 | 2011-08-04 | George Adjabeng | Thiazole And Oxazole Kinase Inhibitors |
ATE510827T1 (de) * | 2007-10-12 | 2011-06-15 | Ingenium Pharmaceuticals Gmbh | Inhibitoren von proteinkinasen |
EP2231625A4 (en) * | 2007-12-13 | 2010-12-29 | Glaxosmithkline Llc | KINASE INHIBITORS BASED ON THIAZOLE AND OXAZOLE |
CA2715658C (en) | 2008-02-15 | 2016-07-19 | Rigel Pharmaceuticals, Inc. | Pyrimidine-2-amine compounds and their use as inhibitors of jak kinases |
GB0805477D0 (en) * | 2008-03-26 | 2008-04-30 | Univ Nottingham | Pyrimidines triazines and their use as pharmaceutical agents |
UA103319C2 (en) | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
WO2010144909A1 (en) | 2009-06-12 | 2010-12-16 | Novartis Ag | Fused heterocyclic compounds and their uses |
JP2013506686A (ja) | 2009-09-30 | 2013-02-28 | プレジデント アンド フェロウズ オブ ハーバード カレッジ | オートファジー阻害遺伝子産物の変調によりオートファジーを変調する方法 |
WO2011059610A1 (en) * | 2009-11-10 | 2011-05-19 | Glaxosmithkline Llc | Benzene sulfonamide thiazole and oxazole compounds |
EP2519517B1 (en) | 2009-12-29 | 2015-03-25 | Dana-Farber Cancer Institute, Inc. | Type ii raf kinase inhibitors |
EP2678336B1 (en) * | 2011-02-24 | 2016-04-20 | Nerviano Medical Sciences S.r.l. | Thiazolylphenyl-benzenesulfonamido derivatives as kinase inhibitors |
WO2013059634A1 (en) | 2011-10-20 | 2013-04-25 | The Regents Of The University Of California | Use of cdk9 inhibitors to reduce cartilage degradation |
JP6106685B2 (ja) * | 2011-11-17 | 2017-04-05 | ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド | C−jun−n−末端キナーゼ(jnk)の阻害剤 |
WO2014063068A1 (en) | 2012-10-18 | 2014-04-24 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
WO2014063061A1 (en) | 2012-10-19 | 2014-04-24 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
WO2014063054A1 (en) | 2012-10-19 | 2014-04-24 | Dana-Farber Cancer Institute, Inc. | Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof |
EP3057956B1 (en) | 2013-10-18 | 2021-05-05 | Dana-Farber Cancer Institute, Inc. | Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7) |
WO2015058126A1 (en) | 2013-10-18 | 2015-04-23 | Syros Pharmaceuticals, Inc. | Heteroaromatic compounds useful for the treatment of prolferative diseases |
PT3126352T (pt) | 2014-04-04 | 2018-12-27 | Syros Pharmaceuticals Inc | Inibidores da quinase dependente de ciclina 7 (cdk7) |
US9862688B2 (en) | 2014-04-23 | 2018-01-09 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged janus kinase inhibitors and uses thereof |
US10017477B2 (en) | 2014-04-23 | 2018-07-10 | Dana-Farber Cancer Institute, Inc. | Janus kinase inhibitors and uses thereof |
JP6930913B2 (ja) | 2014-10-14 | 2021-09-01 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアThe Regents Of The University Of California | 炎症を阻害するためのcdk9及びbrd4阻害剤の使用法 |
US10870651B2 (en) | 2014-12-23 | 2020-12-22 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
JP6861166B2 (ja) | 2015-03-27 | 2021-04-21 | ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド | サイクリン依存性キナーゼの阻害剤 |
EP3307728A4 (en) | 2015-06-12 | 2019-07-17 | Dana Farber Cancer Institute, Inc. | ASSOCIATION THERAPY USING TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS |
CN113336746A (zh) | 2015-08-04 | 2021-09-03 | 常州千红生化制药股份有限公司 | N-(吡啶-2-基)-4-(噻唑-5-基)嘧啶-2-胺类化合物作为治疗性化合物 |
JP7028766B2 (ja) | 2015-09-09 | 2022-03-02 | ダナ-ファーバー キャンサー インスティテュート, インコーポレイテッド | サイクリン依存性キナーゼの阻害剤 |
CN111757881B (zh) * | 2018-01-15 | 2024-05-07 | 澳升医药公司 | 作为治疗剂的5-(嘧啶-4-基)噻唑-2-基脲衍生物 |
CN111039941B (zh) * | 2018-10-12 | 2023-03-21 | 上海医药集团股份有限公司 | 一种含氮杂环化合物、其制备方法及应用 |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5516775A (en) * | 1992-08-31 | 1996-05-14 | Ciba-Geigy Corporation | Further use of pyrimidine derivatives |
CA2174080A1 (en) * | 1993-10-12 | 1995-04-20 | Paul Edward Aldrich | 1n-alkyl-n-arylpyrimidinamines and derivatives thereof |
GB9519275D0 (en) * | 1995-09-21 | 1995-11-22 | Univ Dundee | Substances and their therapeutic use |
GB9523675D0 (en) * | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
DE69736351D1 (de) * | 1996-05-08 | 2006-08-31 | Cyclacel Ltd | Methoden und mittel zur hemmung der cdk4-aktivität |
US6703395B2 (en) * | 1998-03-04 | 2004-03-09 | Institute Of Experimental Botany Of The Academy Of Sciences Of The Czech Republic | Cyclin dependent kinase inhibitor |
AU753015B2 (en) * | 1998-03-04 | 2002-10-03 | Cyclacel Limited | Cyclin dependent kinase inhibitor |
US7045519B2 (en) * | 1998-06-19 | 2006-05-16 | Chiron Corporation | Inhibitors of glycogen synthase kinase 3 |
ATE274510T1 (de) * | 1998-06-19 | 2004-09-15 | Chiron Corp | Glycogen synthase kinase 3 inhibitoren |
CN100355751C (zh) * | 2000-03-29 | 2007-12-19 | 西克拉塞尔有限公司 | 2-取代的4-杂芳基-嘧啶、其组合物及其用途 |
GB0107901D0 (en) * | 2001-03-29 | 2001-05-23 | Cyclacel Ltd | Anti-cancer compounds |
JP4523271B2 (ja) * | 2001-06-01 | 2010-08-11 | バーテックス ファーマシューティカルズ インコーポレイテッド | プロテインキナーゼのインヒビターとして有用なチアゾール化合物 |
US20040181066A1 (en) * | 2001-08-01 | 2004-09-16 | Fraley Mark E. | Tyrosine kinase inhibitors |
CA2460909A1 (en) * | 2001-09-28 | 2003-04-10 | Cyclacel Limited | N-(4-(4-methylthiazol-5-yl) pyrimidin-2-yl) -n-phenylamines as antiproliferative compounds |
GB0226582D0 (en) * | 2002-11-14 | 2002-12-18 | Cyclacel Ltd | Anti-viral compounds |
GB0226583D0 (en) * | 2002-11-14 | 2002-12-18 | Cyclacel Ltd | Compounds |
GB0229581D0 (en) * | 2002-12-19 | 2003-01-22 | Cyclacel Ltd | Use |
EP1610793A2 (en) * | 2003-03-25 | 2006-01-04 | Vertex Pharmaceuticals Incorporated | Thiazoles useful as inhibitors of protein kinases |
EP1648887A1 (en) * | 2003-07-30 | 2006-04-26 | Cyclacel Limited | Pyridinylamino-pyrimidine derivatives as protein kinase inhibitors |
AU2004261484A1 (en) * | 2003-07-30 | 2005-02-10 | Cyclacel Limited | 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors |
EP1678171B1 (en) * | 2003-10-21 | 2016-09-14 | Cyclacel Limited | 2-amino-4-thiazolone-pyrimidine derivatives as protein kinase inhibitors |
JPWO2005113550A1 (ja) * | 2004-05-20 | 2008-03-27 | 三菱ウェルファーマ株式会社 | アミノピリミジン誘導体及びその医薬としての用途 |
-
2004
- 2004-05-26 GB GBGB0411791.7A patent/GB0411791D0/en not_active Ceased
-
2005
- 2005-05-26 CA CA002566051A patent/CA2566051A1/en not_active Abandoned
- 2005-05-26 MX MXPA06013632A patent/MXPA06013632A/es not_active Application Discontinuation
- 2005-05-26 BR BRPI0511616-3A patent/BRPI0511616A/pt not_active IP Right Cessation
- 2005-05-26 CN CNA2005800241399A patent/CN1989138A/zh active Pending
- 2005-05-26 EP EP05748147A patent/EP1756098A2/en not_active Withdrawn
- 2005-05-26 US US11/596,740 patent/US20090137572A1/en not_active Abandoned
- 2005-05-26 AU AU2005247682A patent/AU2005247682A1/en not_active Abandoned
- 2005-05-26 WO PCT/GB2005/002134 patent/WO2005116025A2/en active Application Filing
- 2005-05-26 JP JP2007514117A patent/JP5026259B2/ja not_active Expired - Fee Related
-
2006
- 2006-11-22 IL IL179508A patent/IL179508A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP5026259B2 (ja) | 2012-09-12 |
AU2005247682A1 (en) | 2005-12-08 |
IL179508A0 (en) | 2007-05-15 |
CN1989138A (zh) | 2007-06-27 |
EP1756098A2 (en) | 2007-02-28 |
US20090137572A1 (en) | 2009-05-28 |
CA2566051A1 (en) | 2005-12-08 |
WO2005116025A2 (en) | 2005-12-08 |
MXPA06013632A (es) | 2007-03-23 |
GB0411791D0 (en) | 2004-06-30 |
JP2008500320A (ja) | 2008-01-10 |
WO2005116025A3 (en) | 2006-02-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0511616A (pt) | compostos | |
CY1122336T1 (el) | Eνωσεις πυρρολιου ως αναστολεις πρωτεϊνικων κινασων εrκ και φαρμακευτικες συνθεσεις που περιεχουν αυτες τις ενωσεις | |
ECSP088350A (es) | Pirazolopirimidinas como inhibidores de protein quinasas | |
BR0316152A (pt) | Compostos de pirimidina | |
BRPI0509369A (pt) | azaindóis úteis como inibidores de jak e outras proteìna cinases | |
ATE420883T1 (de) | Pyrrolopyrimidine verwendbar als protein kinase inhibitoren | |
EA201290209A1 (ru) | Новые модуляторы бензопиран киназы | |
DK1951729T3 (da) | Oxygenbundne pyrimidinderivater | |
MX2009013729A (es) | Imidazopirazinas como inhibidores de proteina quinasa. | |
EA200901133A1 (ru) | Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение | |
BR112014033055A8 (pt) | Inibidores seletivos de delta pi3k | |
DOP2006000179A (es) | 7-aza-indazoles sustituidos, composiciones que les contienen, procedimiento de fabricación y utilización | |
BRPI0719195B8 (pt) | inibidores de quinase, seus usos, e composição farmacêutica | |
TW200637547A (en) | Compounds and compositions as protein kinase inhibitors | |
CY1114148T1 (el) | Γεφυρωμενες δικυκλικες αρυλο- και γεφυρωμενες δικυκλικες etepoapyλo-υποκατεστημενες τριαζολες χρησιμες ως αναστολεις toy axl | |
BRPI0720270B8 (pt) | compostos 4-fenil-6-(2,2,2-triflúor-1-fenil etoxi) pirimidina, composição e forma de dosagem sólida | |
ATE527243T1 (de) | Calciumkanal-antagonisten vom typ chinazolinon t | |
MX2009004714A (es) | Derivados de pirazol fusionado 3-aminocarbonilo sustituidos como moduladores de proteina cinasa. | |
EA200802118A1 (ru) | Обладающие ингибирующей активностью в отношении mnk1/mnk2 тиенопиримидины, предназначенные для применения в фармацевтических композициях | |
ATE430747T1 (de) | 2-pyrimidinyl-pyrazolopyridin-erbb- kinaseinhibitoren | |
EA200700118A1 (ru) | Амидосоединения и их применение в качестве лекарственных средств | |
ES2354824T3 (es) | Pirazolo[1,5-a]pirimidinas útiles como inhibidores de proteínas cinasas. | |
ECSP088345A (es) | Nuevas pirazolopirimidinas como inhibidores de quinasa dependientes de ciclina | |
EA201100032A1 (ru) | Соединения пиридина | |
EA201300246A1 (ru) | Ингибиторы тирозинкиназы брутона |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 6A E 7A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012. |